Phase Forward and SGS Life Science Services Continue Collaboration Developing Phase I Trials


Company News Release

SGS Leverages Phase Forward's InForm and Central Designer Solutions for Greater Clinical Trial Efficiencies

Phase Forward and SGS Life Science Services Continue Collaboration Developing Phase I Trials

SGS Leverages Phase Forward’s InForm™ and Central Designer™ Solutions for Greater Clinical Trial Efficiencies

WALTHAM, Mass.--(BUSINESS WIRE <> )--Phase Forward <>  (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced that SGS Life Science Services, a leading contract research organization (CRO), has successfully developed multiple Phase I trials across various therapeutic areas using Phase Forward’s Central Designer tool. The Central Designer technology provides one central and independent environment for building studies, where all teams work within a centralized system and one that allows for reuse of study components. These Phase I trials were highly complex, involving more than 1,500 forms in aggregate, and the teamwork between the two organizations significantly improved the efficiency of the study builds.

A Phase Forward customer since 2002, SGS is one of the largest EU data management CROs, managing nearly 100 clinical trials and processing one million case report form (CRF) pages each year.

“Our first priority is ensuring that our customers have access to the best, most innovative technology for clinical trials,” said Luc Braeken, vice president, global clinical management, SGS. “Our many years of experience with Phase Forward’s InForm technology, and our success with Central Designer, coupled with Phase Forward’s premier services team, has helped further position us in the Phase I space.”

“Better trial management and drug development is highly dependent on the technology being used, and CROs continue to play a critical role in helping to reshape the efficiencies of EDC and related tools,” said Mike Davies, vice president, global CRO partnerships, Phase Forward. “Together, we help biopharmaceutical and medical device firms realize the full benefits of these technologies across all trial phases. We look forward to continued success with SGS in pursuit of this goal.”

About SGS Life Science Services

SGS Life Science Services, a Business unit of the SGS Group, has 30 years of experience as a global contract service organization providing integrated solutions from preclinical activities to Phase I through IV trials, bio-analytical and QC testing. With more than 1,300 employees and 2,000 clinical trials performed, SGS Life Science Services serves the pharmaceutical, biotechnology and medical device industries. SGS Life Science Services Biometrics group is one of the largest EU Data Management CROs, processing over one million CRF pages each year and offering comprehensive expertise, including in-depth experience in EDC, CDISC and extensive high throughput capabilities. The SGS Group is the global leader and innovator in inspection, verification, testing and certification services. Founded in 1878, SGS is recognized as the global benchmark in quality and integrity. With more than 50,000 employees, SGS operates a network of more than 1,000 offices and laboratories around the world. Additional information about SGS is available at <> .

About Phase Forward

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. The company offers proven solutions for electronic data capture (InFormTM), phase I clinic automation (LabPasTM), clinical data management (ClintrialTM), clinical trials signal detection (CTSDTM), strategic pharmacovigilance (Empirica SignalTM) and Signal Management, adverse event reporting (Empirica TraceTM), applied data standards (WebSDMTM) and Web-integrated interactive response technologies (ClarixTM). In addition, the company provides services in the areas of application implementation, hosting and validation, data integration, business process optimization, safety data management and industry standards. Phase Forward’s products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 280 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at <> .

Cautionary Statement

Certain statements made in this press release that are not based on historical information are forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release contains express or implied forward-looking statements relating to, among other things, the performance and features of Phase Forward’s products and services, future business and operations plans of Phase Forward customers and alliance partners, and the ability of Phase Forward’s customers and alliance partners to realize benefits from the use of Phase Forward’s products and services. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond Phase Forward's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things, the ability of Phase Forward’s customers and alliance partners to realize benefits from the use of its products and services, changes in regulatory requirements applicable to Phase Forward’s customers and alliance partners, the manner in which Phase Forward’s customers and alliance partners conduct business and the possibility that their needs or plans may change over time, and competition. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Phase Forward undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by Phase Forward, see the disclosure contained in Phase Forward's public filings with the Securities and Exchange Commission including, without limitation, its most recent Annual Report on Form 10-K.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.